Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04811001 | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations(CAPLAND) | unknown | Phase 2 | 170 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER |
| 1 |
| Feb 21, 2023 |
| clinicaltrials |
| NCT05736991 | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma | unknown | — | 600 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05737589 | Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis | unknown | — | 50 | Xiaorong DongOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04153097 | Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC | unknown | — | 500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05445310 | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer | unknown | Phase 2 | 114 | Peking Union Medical College HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04996927 | 18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC | unknown | — | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05257512 | Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 150 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05430386 | Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC | unknown | Phase 1 | 174 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05533086 | PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer | unknown | — | 20 | Xiaohua ZhuOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05715398 | BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 90 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 0 | Feb 10, 2023 | clinicaltrials |
| NCT05425134 | Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer | unknown | — | 5,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05716672 | Impact of Lazertinib Dose Modification on Effectiveness and Safety | unknown | — | 200 | Pusan National University HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT04895930 | Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(FOCUS-A) | unknown | Phase 2 | 40 | Shanghai Chest HospitalOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05662813 | Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy | unknown | Phase 2 | 55 | West China HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04436406 | PD-L1 Expression in Cancer (PECan Study).(PECan) | unknown | N/A | 30 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651269 | Milciclib in Combination With Gemcitabine in Advanced NSCLC | unknown | Phase 2 | 28 | Tiziana Life Sciences LTDINDUSTRY | 0 | Dec 15, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05648370 | Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery | unknown | — | 60 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT04758481 | Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer | unknown | N/A | 20 | University Hospital OstravaOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03574402 | Phase II Umbrella Study Directed by Next Generation Sequencing(TRUMP) | unknown | Phase 2 | 400 | Guangdong Association of Clinical TrialsOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04211090 | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC(CAP-BRAIN) | unknown | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05611450 | Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy | unknown | N/A | 108 | Chang Gung Memorial HospitalOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603013 | Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0) | unknown | Phase 2 | 45 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05583409 | SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC | unknown | N/A | 72 | Li ZhangOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05577052 | SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases | unknown | N/A | 100 | Wuhan UniversityOTHER | 0 | Oct 13, 2022 | clinicaltrials |
| NCT05574998 | First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial(FTANLCNDG) | unknown | Phase 2 | 100 | Qianfoshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05565677 | Prognostic Value of Lung Cancer MicroAnatomy in 3D(LungCaMa3D) | unknown | — | 50 | Aristotle University Of ThessalonikiOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT05547737 | Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer(NSCLC) | unknown | — | 500 | Henan Cancer HospitalOTHER_GOV | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05548348 | First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation | unknown | Phase 2 | 30 | Chongqing University Cancer HospitalOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04942275 | Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy(PEGASUS) | unknown | Phase 2 / Phase 3 | 60 | University Hospital, BrestOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT04455438 | SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions(STRILL) | unknown | N/A | 15 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04571632 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors(Luscid) | unknown | Phase 2 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT05534113 | Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC | unknown | Phase 2 | 38 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 14, 2022 | clinicaltrials |
| NCT05532527 | Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study(NSCLC) | unknown | N/A | 35 | Henan Provincial People's HospitalOTHER | 0 | Sep 8, 2022 | clinicaltrials |
| NCT05529355 | Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 45 | Anhui Chest HospitalOTHER | 0 | Sep 7, 2022 | clinicaltrials |
| NCT05513664 | Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer | unknown | — | 80 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 21, 2023source: clinicaltrials